StocksMediumUpdated•Originally published 22 October 2026•Updated 22 October 2026•
1 min read
Fractyl Health Restructures Operations to Focus on Revita and Cut Costs
Key Facts
1Fractyl Health announced it is focusing resources on its Revita product following positive topline results from the REMAIN-1 pivotal study.
2The company plans an FDA De Novo submission in late Q4 2026 and expects to reduce quarterly cash burn by approximately 50%.
3The company is discontinuing Rejuva development and reducing its workforce to extend its cash runway into Q2 2027.
Fractyl Health announced it is laying off 45% of its workforce as part of a comprehensive restructuring plan to focus its resources on the Revita product. According to a statement on GlobeNewswire, the company has decided to discontinue its Rejuva program to reduce quarterly cash burn by approximately 50% and extend its financial runway into the second quarter of 2027.
The company plans to submit an FDA De Novo application in late Q4 2026 following positive topline results from the REMAIN-1 pivotal study. GUTS closed at $1.15 on October 21, 2026, with a daily trading range between $1.11 and $1.37.